Comparison of the VERSANT™ HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR™ hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy

Jeffrey J. Germer, Nizar N. Zein, Mohamed A. Metwally, Tanya L. Hoskin, W. Scott Harmsen, Thomas F. Smith, Robin Patel

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hepatitis C virus (HCV)-infected patients were tested for the presence of HCV RNA using two qualitative assays at various time points during interferon-ribavirin therapy. Among patients treated for 48 weeks, transcription-mediated amplification and the COBAS AMPLICOR Hepatitis C Virus Test results at Week 24 predicted subsequent virologic non-response or virologic relapse in 12/15 (80%) and 8/15 (53%) patients, respectively.

Original languageEnglish (US)
Pages (from-to)615-618
Number of pages4
JournalDiagnostic Microbiology and Infectious Disease
Volume47
Issue number4
DOIs
StatePublished - Dec 2003

Fingerprint

Ribavirin
Hepacivirus
Interferons
RNA
Therapeutics
Recurrence

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy
  • Virology
  • Parasitology
  • Microbiology
  • Immunology
  • Applied Microbiology and Biotechnology

Cite this

Comparison of the VERSANT™ HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR™ hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy. / Germer, Jeffrey J.; Zein, Nizar N.; Metwally, Mohamed A.; Hoskin, Tanya L.; Harmsen, W. Scott; Smith, Thomas F.; Patel, Robin.

In: Diagnostic Microbiology and Infectious Disease, Vol. 47, No. 4, 12.2003, p. 615-618.

Research output: Contribution to journalArticle

@article{af35325874a24f9f9c163d9d688fd87d,
title = "Comparison of the VERSANT™ HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR™ hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy",
abstract = "Hepatitis C virus (HCV)-infected patients were tested for the presence of HCV RNA using two qualitative assays at various time points during interferon-ribavirin therapy. Among patients treated for 48 weeks, transcription-mediated amplification and the COBAS AMPLICOR Hepatitis C Virus Test results at Week 24 predicted subsequent virologic non-response or virologic relapse in 12/15 (80{\%}) and 8/15 (53{\%}) patients, respectively.",
author = "Germer, {Jeffrey J.} and Zein, {Nizar N.} and Metwally, {Mohamed A.} and Hoskin, {Tanya L.} and Harmsen, {W. Scott} and Smith, {Thomas F.} and Robin Patel",
year = "2003",
month = "12",
doi = "10.1016/S0732-8893(03)00149-4",
language = "English (US)",
volume = "47",
pages = "615--618",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Comparison of the VERSANT™ HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR™ hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy

AU - Germer, Jeffrey J.

AU - Zein, Nizar N.

AU - Metwally, Mohamed A.

AU - Hoskin, Tanya L.

AU - Harmsen, W. Scott

AU - Smith, Thomas F.

AU - Patel, Robin

PY - 2003/12

Y1 - 2003/12

N2 - Hepatitis C virus (HCV)-infected patients were tested for the presence of HCV RNA using two qualitative assays at various time points during interferon-ribavirin therapy. Among patients treated for 48 weeks, transcription-mediated amplification and the COBAS AMPLICOR Hepatitis C Virus Test results at Week 24 predicted subsequent virologic non-response or virologic relapse in 12/15 (80%) and 8/15 (53%) patients, respectively.

AB - Hepatitis C virus (HCV)-infected patients were tested for the presence of HCV RNA using two qualitative assays at various time points during interferon-ribavirin therapy. Among patients treated for 48 weeks, transcription-mediated amplification and the COBAS AMPLICOR Hepatitis C Virus Test results at Week 24 predicted subsequent virologic non-response or virologic relapse in 12/15 (80%) and 8/15 (53%) patients, respectively.

UR - http://www.scopus.com/inward/record.url?scp=0347986543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347986543&partnerID=8YFLogxK

U2 - 10.1016/S0732-8893(03)00149-4

DO - 10.1016/S0732-8893(03)00149-4

M3 - Article

C2 - 14711484

AN - SCOPUS:0347986543

VL - 47

SP - 615

EP - 618

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 4

ER -